We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+5.84%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$514M
AUM Growth
+$108M
Cap. Flow
+$168M
Cap. Flow %
32.76%
Top 10 Hldgs %
77.97%
Holding
36
New
6
Increased
8
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$50.7M
2
RCUS icon
Arcus Biosciences
RCUS
+$43.6M
3
FDMT icon
4D Molecular Therapeutics
FDMT
+$17.6M
4
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$17.1M
5
KROS icon
Keros Therapeutics
KROS
+$17M

Top Sells

Rank Stock Value
1
CRIS icon
Curis
CRIS
+$18M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$4.5M
3
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$4.2M
4
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$3.69M
5
IMA
ImageneBio Inc
IMA
+$3.47M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$95.5M 18.59%
2,020,911
+425,000
+27% +$16.7M
RCUS icon
2
Arcus Biosciences
RCUS
$3.44B
$84.8M 16.5%
2,095,231
+1,125,067
+116% +$43.6M
NBP
3
NovaBridge Biosciences American Depositary Shares
NBP
$206M
$49.7M 9.68%
1,049,691
+285,230
+37% +$17.1M
FDMT icon
4
4D Molecular Therapeutics
FDMT
$575M
$34M 6.62%
1,551,070
+719,803
+87% +$17.6M
BBIO icon
5
BridgeBio Pharma
BBIO
$15.9B
$29.5M 5.74%
1,767,486
+1,198,072
+210% +$50.7M
CLDX icon
6
Celldex Therapeutics
CLDX
$2.77B
$29.4M 5.73%
761,398
– –
ITOS
7
DELISTED
iTeos Therapeutics
ITOS
$21M 4.08%
+450,776
New +$15M
KROS icon
8
Keros Therapeutics
KROS
$211M
$19.9M 3.87%
+340,214
New +$17M
STOK icon
9
Stoke Therapeutics
STOK
$1.81B
$18.8M 3.66%
783,769
+486,947
+164% +$11.6M
VERA icon
10
Vera Therapeutics
VERA
$2.76B
$17.9M 3.49%
670,940
-25,186
-4% -$557K
GOSS icon
11
Gossamer Bio
GOSS
$83.2M
$17.1M 3.33%
1,513,138
– –
ARVN icon
12
Arvinas
ARVN
$517M
$14.7M 2.85%
178,500
+10,000
+6% +$814K
IPSC icon
13
Century Therapeutics
IPSC
$406M
$11.1M 2.17%
702,623
+100,000
+17% +$1.88M
RNAM
14
DELISTED
Avidity Biosciences
RNAM
$10.6M 2.07%
446,641
– –
KDNY
15
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$8.15M 1.59%
+500,000
New +$7.12M
RXDX
16
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$7.91M 1.54%
200,000
– –
DYN icon
17
Dyne Therapeutics
DYN
$3.92B
$6.94M 1.35%
583,649
– –
CTKB icon
18
Cytek Biosciences
CTKB
$597M
$6.53M 1.27%
400,000
-100,000
-20% -$2.09M
CRDF icon
19
Cardiff Oncology
CRDF
$68.3M
$5.91M 1.15%
982,753
– –
IMVT icon
20
Immunovant
IMVT
$8.27B
$4.88M 0.95%
+572,862
New +$4.73M
MLTX icon
21
MoonLake Immunotherapeutics
MLTX
$1.64B
$3.96M 0.77%
400,000
– –
GLUE icon
22
Monte Rosa Therapeutics
GLUE
$2.07B
$3.06M 0.6%
150,000
– –
AMAM
23
DELISTED
Ambrx Biopharma Inc
AMAM
$3.04M 0.59%
336,868
-13,132
-4% -$147K
JYAC
24
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.93M 0.57%
300,000
– –
OLMA icon
25
Olema Pharmaceuticals
OLMA
$1B
$2.17M 0.42%
+231,417
New +$4.79M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Octagon Capital Advisors held 36 positions worth $514M, up 27% from $406M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Octagon Capital Advisors deployed $168M of net new capital in Q4 2021, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Keros Therapeutics: 340,214 shares worth $19.9M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Omega Therapeutics, Inc. Common Stock, an estimated $3.69M trimmed.

  • Octagon Capital Advisors's largest Q4 2021 buy was Keros Therapeutics: 340,214 shares worth $19.9M.
  • Octagon Capital Advisors added most to BridgeBio Pharma in Q4 2021, an estimated $50.7M increase.
  • Octagon Capital Advisors's biggest Q4 2021 reduction was Omega Therapeutics, Inc. Common Stock, cutting an estimated $3.69M.
  • Octagon Capital Advisors fully exited Curis in Q4 2021, selling an estimated $18M.
  • Octagon Capital Advisors's ten largest holdings make up 78% of its $514M portfolio in Q4 2021.
  • Octagon Capital Advisors opened 6 new positions and closed 8 in Q4 2021.
  • Octagon Capital Advisors's portfolio value rose 27% quarter-over-quarter to $514M.

Based on Octagon Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.